Carbapenemase-producing Enterobacteriaceae in the UK: a national study (EuSCAPE-UK) on prevalence, incidence, laboratory detection methods and infection control measures
Pascale Trepanier,Kim Mallard,Danièle Meunier,Rachel Pike,Derek Brown,Janet P. Ashby,Hugo Donaldson,F. Mustafa Awad-El-Kariem,Indran Balakrishnan,Marc Cubbon,Paul R. Chadwick,Michael Doughton,Rachael Doughton,Fiona Hardiman,Graham Harvey,Carolyne Horner,John Lee,Jonathan Lewis,Anne Loughrey,Rohini Manuel,Helena Parsons,John D. Perry,Gemma Vanstone,Graham White,Nandini Shetty,John Coia,Camilla Wiuff,Katie L. Hopkins,Neil Woodford
DOI: https://doi.org/10.1093/jac/dkw414
2016-09-29
Journal of Antimicrobial Chemotherapy
Abstract:OBJECTIVES: To estimate UK prevalence and incidence of clinically significant carbapenemase-producing Enterobacteriaceae (CPE), and to determine epidemiological characteristics, laboratory methods and infection prevention and control (IPC) measures in acute care facilities.METHODS: A 6 month survey was undertaken in November 2013-April 2014 in 21 sentinel UK laboratories as part of the European Survey on Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) project. Up to 10 consecutive, non-duplicate, clinically significant and carbapenem-non-susceptible isolates of Escherichia coli or Klebsiella pneumoniae were submitted to a reference laboratory. Participants answered a questionnaire on relevant laboratory methods and IPC measures.RESULTS: Of 102 isolates submitted, 89 (87%) were non-susceptible to ≥1 carbapenem, and 32 (36%) were confirmed as CPE. CPE were resistant to most antibiotics, except colistin (94% susceptible), gentamicin (63%), tigecycline (56%) and amikacin (53%). The prevalence of CPE was 0.02% (95% CI = 0.01%-0.03%). The incidence of CPE was 0.007 per 1000 patient-days (95% CI = 0.005-0.010), with north-west England the most affected region at 0.033 per 1000 patient-days (95% CI = 0.012-0.072). Recommended IPC measures were not universally followed, notably screening high-risk patients on admission (applied by 86%), using a CPE 'flag' on patients' records (70%) and alerting neighbouring hospitals when transferring affected patients (only 30%). Most sites (86%) had a laboratory protocol for CPE screening, most frequently using chromogenic agar (52%) or MacConkey/CLED agars with carbapenem discs (38%).CONCLUSIONS: The UK prevalence and incidence of clinically significant CPE is currently low, but these MDR bacteria affect most UK regions. Improved IPC measures, vigilance and monitoring are required.
pharmacology & pharmacy,infectious diseases,microbiology